Bangalore, Karnataka, India OncoStem Diagnostics, an oncology-focused company that enables personalised cancer treatment, has successfully completed its first-ever comparative study with the prognostic test Oncotype DX. The study, conducted using samples from OncoStem’s study partners in India, USA and Spain, was recently published in the journal “Cancer Medicine”. The performance of the two tests were found to be equivalent. CanAssist Breast: Made in India, Made for the World OncoStem’s CanAssist Breast is a prognostic test for early-stage hormone receptor-positive breast cancer patients. It makes customized treatment possible by analysing the…
Read MoreNew Study Reports OncoStem’s CanAssist Breast Equivalent to Gold Standard
